Immunocore Holdings plc Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Immunocore Holdings plc (IMCR) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$5.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- Immunocore Holdings plc effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$6.13M, a 172.80% decline year-over-year.
- Immunocore Holdings plc effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $8.43M.
- Immunocore Holdings plc effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$800.00K, a 135.91% decline year-over-year.
- Immunocore Holdings plc effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $2.23M.
- Immunocore Holdings plc effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $26.66M.
- Immunocore Holdings plc effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$1.71M, a 120.60% decline from fiscal 2023.
- Immunocore Holdings plc effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $8.29M.
- Immunocore Holdings plc effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$12.65M, a 2123.36% decline from fiscal 2021.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.52M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$6.13M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $26.66M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $28.11M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $20.29M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $8.43M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$1.71M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $11.33M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$959.00K 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$800.00K 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $8.29M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | -$2.49M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $5.62M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $2.23M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$12.65M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $625.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |